BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8831991)

  • 1. Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.
    Höglund M; Smedmyr B; Simonsson B; Tötterman T; Bengtsson M
    Bone Marrow Transplant; 1996 Jul; 18(1):19-27. PubMed ID: 8831991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of peripheral blood progenitor cells mobilized by nartograstim (N-terminal replaced granulocyte colony-stimulating factor) in normal volunteers.
    Maruyama K; Tsuji K; Tanaka R; Yamada K; Kodera Y; Nakahata T
    Bone Marrow Transplant; 1998 Aug; 22(4):313-20. PubMed ID: 9722064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of enriched CD34+ cells from healthy volunteers and those from patients treated with chemotherapy plus granulocyte colony-stimulating factor (G-CSF).
    Suzuki T; Muroi K; Tomizuka H; Amemiya Y; Miura Y
    Stem Cells; 1995 May; 13(3):273-80. PubMed ID: 7542113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
    Huhn RD; Yurkow EJ; Tushinski R; Clarke L; Sturgill MG; Hoffman R; Sheay W; Cody R; Philipp C; Resta D; George M
    Exp Hematol; 1996 Jun; 24(7):839-47. PubMed ID: 8647235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both.
    Ho AD; Young D; Maruyama M; Corringham RE; Mason JR; Thompson P; Grenier K; Law P; Terstappen LW; Lane T
    Exp Hematol; 1996 Nov; 24(13):1460-8. PubMed ID: 8950228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.
    Körbling M; Anderlini P; Durett A; Maadani F; Bojko P; Seong D; Giralt S; Khouri I; Andersson B; Mehra R; vanBesien K; Mirza N; Przepiorka D; Champlin R
    Bone Marrow Transplant; 1996 Dec; 18(6):1073-9. PubMed ID: 8971375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Sirohi B; Millar B; Shepherd V; Saso R; Rowland A; Long S; Cabral S; Horton C; Mehta J
    Bone Marrow Transplant; 2000 Mar; 25(5):501-5. PubMed ID: 10713626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human granulocyte colony-stimulating factor can mobilize sufficient amounts of peripheral blood stem cells in healthy volunteers for allogeneic transplantation.
    Matsunaga T; Sakamaki S; Kohgo Y; Ohi S; Hirayama Y; Niitsu Y
    Bone Marrow Transplant; 1993 Feb; 11(2):103-8. PubMed ID: 7679596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery are enriched with early Thy-1+ hematopoietic progenitor cells.
    Haas R; Möhle R; Pförsich M; Fruehauf S; Witt B; Goldschmidt H; Hunstein W
    Blood; 1995 Apr; 85(7):1936-43. PubMed ID: 7535595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors.
    Martínez C; Urbano-Ispizua A; Rozman M; Rovira M; Marín P; Montfort N; Carreras E; Montserrat E
    Bone Marrow Transplant; 1999 Jan; 23(1):15-9. PubMed ID: 10037045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low incidence of severe aGVHD and accelerating hemopoietic reconstitution in allo-BMT using lenograstim stimulated BM cells.
    Ji S; Chen H; Wang H; Ma J; Pan S; Xue M; Zhu L; Liu J; Xiao M; Zhou L
    Chin Med J (Engl); 2001 Feb; 114(2):191-5. PubMed ID: 11780205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of L-selectin, VLA-4, and LFA-1 on CD34+ progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery.
    Möhle R; Murea S; Kirsch M; Haas R
    Exp Hematol; 1995 Dec; 23(14):1535-42. PubMed ID: 8542944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of granulocyte colony-stimulating factor in mobilization and transplantation of peripheral blood progenitor and stem cells .
    Haas R; Murea S
    Cytokines Mol Ther; 1995 Dec; 1(4):249-70. PubMed ID: 9384679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and adverse events following 5-day repeated administration of lenograstim, a recombinant human granulocyte colony-stimulating factor, in healthy subjects.
    Akizuki S; Mizorogi F; Inoue T; Sudo K; Ohnishi A
    Bone Marrow Transplant; 2000 Nov; 26(9):939-46. PubMed ID: 11100272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin enhances neutrophil production by bone marrow hematopoietic progenitors with the aid of stem cell factor in congenital neutropenia.
    Sawai N; Koike K; Mwamtemi HH; Ito S; Kurokawa Y; Sakashita K; Kinoshita T; Higuchi T; Takeuchi K; Shiohara M; Kamijo T; Higuchi Y; Miyazaki H; Kato T; Kobayashi M; Miyake M; Yasui K; Komiyama A
    J Leukoc Biol; 2000 Jul; 68(1):137-43. PubMed ID: 10914501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.